Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.

Forte IM, Indovina P, Iannuzzi CA, Cirillo D, Di Marzo D, Barone D, Capone F, Pentimalli F, Giordano A.

Int J Oncol. 2019 Jun;54(6):2189-2199. doi: 10.3892/ijo.2019.4788. Epub 2019 Apr 16.

PMID:
31081046
2.

Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.

Wu Q, Cao Z, Xiao W, Zhu L, Xie Q, Li L, Zhang B, Zhao W.

Cell Physiol Biochem. 2018;51(6):2536-2546. doi: 10.1159/000495923. Epub 2018 Dec 11.

3.

[RITA combined with temozolomide inhibits the proliferation of human glioblastoma U87 cells].

He XY, Feng XL, Song XP, Zeng HC, Cao ZX, Xiao WW, Zhang B, Wu QH.

Nan Fang Yi Ke Da Xue Xue Bao. 2016 Oct 20;36(10):1423-1428. Chinese.

PMID:
27777210
4.

SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment.

Ceccherini E, Indovina P, Zamperini C, Dreassi E, Casini N, Cutaia O, Forte IM, Pentimalli F, Esposito L, Polito MS, Schenone S, Botta M, Giordano A.

J Cell Biochem. 2015 May;116(5):856-63. doi: 10.1002/jcb.25042.

PMID:
25521525
5.

Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.

Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, Mattioli E, Iannuzzi CA, Budillon A, Giordano A, Pentimalli F.

Cell Cycle. 2014;13(4):652-65. doi: 10.4161/cc.27546. Epub 2013 Dec 17.

PMID:
24345738
6.

Dovitinib enhances temozolomide efficacy in glioblastoma cells.

Thanasupawat T, Natarajan S, Rommel A, Glogowska A, Bergen H, Krcek J, Pitz M, Beiko J, Krawitz S, Verma IM, Ghavami S, Klonisch T, Hombach-Klonisch S.

Mol Oncol. 2017 Aug;11(8):1078-1098. doi: 10.1002/1878-0261.12076. Epub 2017 Jun 5.

7.

A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.

Kim SS, Rait A, Kim E, Pirollo KF, Chang EH.

Nanomedicine. 2015 Feb;11(2):301-11. doi: 10.1016/j.nano.2014.09.005. Epub 2014 Sep 18.

8.

O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.

Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M.

J Neurochem. 2006 Feb;96(3):766-76. Epub 2006 Jan 9.

9.

GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.

Wang HH, Chang TY, Lin WC, Wei KC, Shin JW.

Sci Rep. 2017 Aug 18;7(1):8814. doi: 10.1038/s41598-017-06851-3.

10.

Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.

Wiegering A, Matthes N, Mühling B, Koospal M, Quenzer A, Peter S, Germer CT, Linnebacher M, Otto C.

Neoplasia. 2017 Apr;19(4):301-309. doi: 10.1016/j.neo.2017.01.007. Epub 2017 Mar 9.

11.

Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.

Rubner Y, Muth C, Strnad A, Derer A, Sieber R, Buslei R, Frey B, Fietkau R, Gaipl US.

Radiat Oncol. 2014 Mar 30;9(1):89. doi: 10.1186/1748-717X-9-89.

12.

The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.

Roh JL, Ko JH, Moon SJ, Ryu CH, Choi JY, Koch WM.

Cancer Lett. 2012 Dec 1;325(1):35-41. doi: 10.1016/j.canlet.2012.05.020. Epub 2012 May 22.

PMID:
22634494
13.

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.

Cen L, Carlson BL, Pokorny JL, Mladek AC, Grogan PT, Schroeder MA, Decker PA, Anderson SK, Giannini C, Wu W, Ballman KV, Kitange GJ, Sarkaria JN.

Neuro Oncol. 2013 Jun;15(6):735-46. doi: 10.1093/neuonc/not010. Epub 2013 Mar 10.

14.

RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.

Shin D, Kim EH, Lee J, Roh JL.

Redox Biol. 2017 Oct;13:219-227. doi: 10.1016/j.redox.2017.05.025. Epub 2017 Jun 1.

15.

Multifaceted resistance of gliomas to temozolomide.

Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM.

Clin Cancer Res. 2002 Aug;8(8):2725-34.

16.

Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.

Taspinar M, Ilgaz S, Ozdemir M, Ozkan T, Oztuna D, Canpinar H, Rey JA, Sunguroğlu A, Castresana JS, Ugur HC.

Tumour Biol. 2013 Jun;34(3):1935-47. doi: 10.1007/s13277-013-0738-7. Epub 2013 Mar 22.

PMID:
23519841
17.

Caffeine Sensitizes U87-MG Human Glioblastoma Cells to Temozolomide through Mitotic Catastrophe by Impeding G2 Arrest.

Li N, Zhang P, Kiang KMY, Cheng YS, Leung GKK.

Biomed Res Int. 2018 Jun 28;2018:5364973. doi: 10.1155/2018/5364973. eCollection 2018.

18.

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.

Naumann SC, Roos WP, Jöst E, Belohlavek C, Lennerz V, Schmidt CW, Christmann M, Kaina B.

Br J Cancer. 2009 Jan 27;100(2):322-33. doi: 10.1038/sj.bjc.6604856. Epub 2009 Jan 6.

19.

Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.

Castro-Gamero AM, Borges KS, Moreno DA, Suazo VK, Fujinami MM, de Paula Gomes Queiroz R, de Oliveira HF, Carlotti CG Jr, Scrideli CA, Tone LG.

Invest New Drugs. 2013 Aug;31(4):858-70. doi: 10.1007/s10637-012-9917-4. Epub 2013 Jan 9.

PMID:
23299390
20.

Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?

He Y, Kaina B.

Int J Mol Sci. 2019 Mar 28;20(7). pii: E1562. doi: 10.3390/ijms20071562.

Supplemental Content

Support Center